Loading...

Q32 Bio Inc.

QTTB•NASDAQ
Healthcare
Biotechnology
$3.32
$1.81(119.87%)

Q32 Bio Inc. (QTTB) Stock Overview

Explore Q32 Bio Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.4/100

Key Financials

Market Cap41.2M
P/E Ratio-0.49
EPS (TTM)$-7.57
ROE-4.47%
Fundamental Analysis

AI Price Forecasts

1 Week$1.95
1 Month$-0.02
3 Months$22.41
1 Year Target$2.50

QTTB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Q32 Bio Inc. (QTTB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 36.19, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.50.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.49 and a market capitalization of 41.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

36.19RSI (14)
-0.08MACD
16.21ADX
Revenue Growth
100.00%
↑ 100.00%
Profit Growth
$-4.90
↑ 11.18%
EPS Growth
$-4.90
↓ 13.53%
Operating Margin
0.00%
↓ 36.98%
ROE
-447.33%
↑ 11.18%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
1
Buy
2
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$64.00
Average$79.67
High$95.00

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

CEO

Jodie Pope Morrison

Employees

28

Headquarters

830 Winter Street, Waltham, MA

Founded

2018

Frequently Asked Questions

;